S.NO.	Company/ University	Head of Company	Country/ Place	Last Vaccine by Company	Trials Date	Expected Date of Result	Technology Used for CoVID 19 Vaccine	Expected Roll Out
1.	Altimmune Inc.	Dr. Vipin Garg	US	NasoVax	April 2020 (Expected)	NA	Intranasal Adenovirus Vector Vaccine
2.	CanSino Biologics	Yu Xuefeng	China	SARS-CoV spike protein	23/03/2020 Phase I		Single Used Bio-reactor System
3.	Clover Biopharmaceuticals Inc, GlaxoSmithKline plc & Dynavax Technologies Corp.	Pen Liang; Emma Natasha Walmsley and CEPI	China	–	May 2020	NA	Trimer tag Technology
4.	CureVac AG	Pierre Kemula and CEPI	Germany	–	April 2020 (expected)	NA	mRNA Based vaccine
5.	Expres2ion Biotechnologies ApS	Dr. Martin Roland Jensen	Denmark	MERS and SARS	January 2021	NA	Insect Cell Expression
6.	Generex Biotechnology; Biology Institute of Shandong Academy of Sciences	S. Gail Eckhardt and Melinda Foundation	China & US	–	May 2020	NA	Li-key Immune system Activation
7.	Ibio Inc; Beijing CC Pharming Ltd.	Robert B. Kay	China	–	Approval waited for clinical trials	NA	FastPharming Sytem (Plant Produced)
8.	Imperial College of London	Robin Shattock and CEPI	UK	–	April 2020 (expected)	NA	Antibody therapy
9.	Inovio Pharma; Beijing Advaccine Biotech. Co. Ltd; Genome Lifescience Inc.	J. Joseph Kim and Funds By Bill Gates	China & US	MERS	April 2020 (Human trials expected)	September 2020	DNA Vaccine
10.	Linearx Inc; Takis Biotech	James Hayward	New York & Italy		April 2020 (expected)	NA	Polymerase Chain Reaction
11.	Medicago Inc.	Dr. Bruce Clark	Canada	SARS CoV 2 gene	July 2020 (expected)	NA	Basic Antibodies response
12.	Moderna Therapeutics Inc.; Kaiser Permanente Health Research Inc.; NIAID	Bill Gates and CEPI	US	Zika Vaccine, SARS 1	16/03/2020 (Human trial)	NA	mRNA based Vaccine
13.	Novavax Inc.	Staney C. Erck and CEPI	US	MERS	May 2020 (expected)	NA	Nanoparticles vaccine
14.	The Jenner Institute; University of Oxford	Prof. Adrian Hill	UK	MERS	28/03/2020 (Phase I)	NA	Adenovirus Vector Encoding
15.	Stermirna therapeutics Co. Ltd.; Tongji University	Li Hangwen	China	–	April 2020 (expected)	NA	mRNA based vaccine
16.	University of Queensland	Peter Hoj and CEPI	Australia	–	May 2020 (expected)	NA	Protein subunit based
17.	University of Saskatchewan	Richard Peter Stoicheff	Canada	–	NA	NA	Different strains of coronavirus
18.	Vaxart Inc.	Wouter W. Latour	UK	–	June 2020 (expected)	NA	Recombinant protein vaccine
19.	Vaxil Bio Ltd.	Ari S. Kellen	Israel	–	July 2020 (expected)	NA	Peptide vaccine based on bioinformatics
20.	Walter Reed Army Institute of Research and US Army Medical Research and Development Command	Col. Deydre S. Teyhen	US	Ebola	July 2020 (expected)	NA	MERS research
21.	Zydus Cadilla	Pankaj Patel	India	–	NA	NA	rMeasles Virus vector based
22.	Mayo Vaccine Research Group	Dr. Gregory Poland	China	–	25/03/2020	NA	Based on Peptide Subunit
23.	University of Western Ontario	–	Canada	–	May 2020 (expected)	NA	Bioinformatics and genetic imaging
24.	National School of Tropical Medicine	Peter Hotez	US	SARS 1	May 2020 (expected)	NA	Development from SARS
25.	Cambridge University	Jonathan Henley	UK	Ebola	Looking for Funds	NA	Antibodies induced enhancing
26.	State Key Laboratory for Emerging Infectious Diseases	Xiang Zhang	Hong Kong, China	H1N1	April 2020	NA	Based on Flu Vaccine
27.	BioNTech SE and Pfizer Inc.	Ugur Sahin	Germany	Cancer related	April 2020 (Expected)	NA	mRNA baaed
28.	CytoDyn Inc.	Nader Z. Pourhassan	USA	HIV	April 2020 (Expected)	NA	Antibodies response based
29.	Heat Biologics Inc.	Jeffrey Wolf	USA	Immunotherapy	April 2020 (Expected)	NA	Based on Flu Vaccine
30.	Johnson & Johnson	Alex Gorsky	USA	HIV	September 2020	NA	mRNA Based
31.	Regeneron Pharmaceuticals Inc	Leonard Schleifer	USA	Ebola	May 2020	NA	Peptide bond Based
32.	Sanofi	Paul Hudson	France	Rubella	April 2020 (Expected)	NA	–
33.	India’s Serum Institute	Cyrus Poonawalla	India	Swine Fly	April 2020 (Expected)	January 2021	Antibodies response Based
34.	Bharat Biotech	Dr. Krishna Ella	India	RotaVac	April 2020 (Expected)	December 2020	Nasal Vaccine
35.	GeoVax and BravoVax	Farshad Guirakhkoo	US	HIV	NA	NA	–
36.	University of Pittsburgh	Louis Falo	US	MERS	2 April 2020 Preclinical Trial	NA	Based on SARS CoV 1 Vaccine